Temporal relationship between antitumor necrosis factor-α antibody therapy and recrudescence of head and neck squamous cell carcinoma

Laryngoscope

Volumn 118, Issue 3, 2008, Pages 450-452

  Engel, Samuel H ^a   Hullar, Timothy E ^a   Adkins, Douglas R ^a   Thorstad, Wade L ^a   Sunwoo, John B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abscess; Head and neck cancer; Immune; Immune system; Infliximab; Malignancy; Remicade; Squamous cell carcinoma; TNF inhibitors; Tumor necrosis factor

Indexed keywords

CISPLATIN; FLUOROURACIL; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABSCESS; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DISEASE EXACERBATION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; LARYNGOSCOPY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; HEAD AND NECK TUMOR; IMMUNOLOGY; TIME; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; GASTROINTESTINAL AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42449084140     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31815abf4c     Document Type: Article

References (8)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.
2. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-974.
3. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943-945.
4. Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35:837-855.
5. Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004;50:S75-77.
6. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-3158.
7. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4:565-573.
8. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002;13:135-141.